Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myomo (MYO) EBITDA (2017 - 2025)

Myomo filings provide 9 years of EBITDA readings, the most recent being -$3.5 million for Q3 2025.

  • On a quarterly basis, EBITDA fell 267.34% to -$3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.9 million, a 41.44% decrease, with the full-year FY2024 number at -$6.2 million, up 24.6% from a year prior.
  • EBITDA hit -$3.5 million in Q3 2025 for Myomo, up from -$4.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$245314.0 in Q4 2024 to a low of -$4.6 million in Q2 2025.
  • Median EBITDA over the past 5 years was -$2.7 million (2023), compared with a mean of -$2.5 million.
  • Biggest five-year swings in EBITDA: skyrocketed 89.92% in 2024 and later plummeted 311.66% in 2025.
  • Myomo's EBITDA stood at -$2.7 million in 2021, then grew by 17.61% to -$2.2 million in 2022, then dropped by 9.14% to -$2.4 million in 2023, then skyrocketed by 89.92% to -$245314.0 in 2024, then crashed by 1333.88% to -$3.5 million in 2025.
  • The last three reported values for EBITDA were -$3.5 million (Q3 2025), -$4.6 million (Q2 2025), and -$3.5 million (Q1 2025) per Business Quant data.